Interestingly, the RNAPII transcriptional machinery of the cancer cells adapts to upregulate and recruit other transcription factors, such as glucocorticoid receptor (GR) and AR splice variants, to bypass blockade of AR transcriptional activity and continue driving disease progression and therapy resistance in patients treated with anti-AR therapies [7,8,9,10,11,12,13,14,15]. Here, NR3C1 is linked to cancer.